2021-2022年度最新SCI期刊列表数据已经更新，欢迎查询！ 如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | MOLECULAR CANCER THERAPEUTICS MOL CANCER THER LetPub评分 7.9
51人评分
我要评分
声誉 8.8 影响力 6.7 速度 9.6 | |||||||||||||||||||||
| 期刊ISSN | 1535-7163 | 微信扫码收藏此期刊 | ||||||||||||||||||||
| E-ISSN | 1538-8514 | |||||||||||||||||||||
| 2021-2022最新影响因子 （数据来源于搜索引擎） | 注册或登录后，查看影响因子和历年趋势图 | |||||||||||||||||||||
| 2021-2022自引率 | 1.40%注册或登录后，查看自引率趋势图 | |||||||||||||||||||||
| h-index | 157 | |||||||||||||||||||||
| CiteScore |
| |||||||||||||||||||||
| 期刊简介 | Molecular Cancer Therapeutics will focus on basic research that has implications for cancer therapeutics in the following areas: Experimental Cancer Therapeutics, Identification of Molecular Targets, Targets for Chemoprevention, New Models, Cancer Chemistry and Drug Discovery, Molecular and Cellular Pharmacology, Molecular Classification of Tumors, and Bioinformatics and Computational Molecular Biology. The journal provides a publication forum for these emerging disciplines that is focused specifically on cancer research. Papers are stringently reviewed and only those that report results of novel, timely, and significant research and meet high standards of scientific merit will be accepted for publication. | |||||||||||||||||||||
| 期刊官方网站 | http://mct.aacrjournals.org/ | |||||||||||||||||||||
| 期刊投稿网址 | http://mct.msubmit.net/cgi-bin/main.plex | |||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||
| 通讯方式 | AMER ASSOC CANCER RESEARCH, 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, USA, PA, 19106-4404 | |||||||||||||||||||||
| 出版商 | American Association for Cancer Research Inc. | |||||||||||||||||||||
| 涉及的研究方向 | 医学-肿瘤学 | |||||||||||||||||||||
| 出版国家或地区 | UNITED STATES | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | Monthly | |||||||||||||||||||||
| 出版年份 | 2001 | |||||||||||||||||||||
| 年文章数 | 230注册或登录后，查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 2.94% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 93.04% | |||||||||||||||||||||
| WOS期刊SCI分区 （ 2021-2022年最新版） | WOS分区等级：2区
| |||||||||||||||||||||
| 中科院《国际期刊预警 名单（试行）》名单 | 2021年12月发布的2021版：不在预警名单中 2021年01月发布的2020版：不在预警名单中 | |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月最新基础版） | 注册或登录后，查看中科院SCI期刊分区趋势图
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月最新升级版） |
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2020年12月旧的升级版） |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) Scopus (CiteScore) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1535-7163%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 平均3月 | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 约50% | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 注册或登录后，查看自引率趋势图 |
| 注册或登录后，查看中科院SCI期刊分区趋势图 |
| 注册或登录后，查看年文章数趋势图 |
| 中国学者近期发表的论文 | |
| 1. | Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non-Small Cell Lung Cancer. Author: Feng J, Zhang S, Wu K, Wang B, Wong JY, Jiang H, Xu R, Ying L, Huang H, Zheng X, Chen X, Ma S. Journal: Mol Cancer Ther. 2016 May;15(5):842-53. doi: 10.1158/1535-7163.MCT-15-0445. Epub 2016 Feb 2. PubMed |
| 2. | Bortezomib Inhibits Giant Cell Tumor of Bone through Induction of Cell Apoptosis and Inhibition of Osteoclast Recruitment, Giant Cell Formation, and Bone Resorption. Author: Xu L, Luo J, Jin R, Yue Z, Sun P, Yang Z, Yang X, Wan W, Zhang J, Li S, Liu M, Xiao J. Journal: Mol Cancer Ther. 2016 May;15(5):854-65. doi: 10.1158/1535-7163.MCT-15-0669. Epub 2016 Feb 9. PubMed |
| 3. | Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53. Author: Karan G, Wang H, Chakrabarti A, Karan S, Liu Z, Xia Z, Gundluru M, Moreton S, Saunthararajah Y, Jackson MW, Agarwal MK, Wald DN. Journal: Mol Cancer Ther. 2016 Apr;15(4):574-82. doi: 10.1158/1535-7163.MCT-15-0467. Epub 2016 Feb 16. PubMed |
| 4. | Long Noncoding RNA PVT1 Promotes Non-Small Cell Lung Cancer Cell Proliferation through Epigenetically Regulating LATS2 Expression. Author: Wan L, Sun M, Liu GJ, Wei CC, Zhang EB, Kong R, Xu TP, Huang MD, Wang ZX. Journal: Mol Cancer Ther. 2016 May;15(5):1082-94. doi: 10.1158/1535-7163.MCT-15-0707. Epub 2016 Feb 23. PubMed |
| 5. | Chikusetsusaponin IVa Butyl Ester (CS-IVa-Be), a Novel IL6R Antagonist, Inhibits IL6/STAT3 Signaling Pathway and Induces Cancer Cell Apoptosis. Author: Yang J, Qian S, Cai X, Lu W, Hu C, Sun X, Yang Y, Yu Q, Gao SP, Cao P. Journal: Mol Cancer Ther. 2016 Jun;15(6):1190-200. doi: 10.1158/1535-7163.MCT-15-0551. Epub 2016 Feb 29. PubMed |
| 6. | Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma. Author: Gifford JB, Huang W, Zeleniak AE, Hindoyan A, Wu H, Donahue TR, Hill R. Journal: Mol Cancer Ther. 2016 May;15(5):1043-52. doi: 10.1158/1535-7163.MCT-15-0774. Epub 2016 Mar 3. PubMed |
| 7. | BRD4 Regulates EZH2 Transcription through Upregulation of C-MYC and Represents a Novel Therapeutic Target in Bladder Cancer. Author: Wu X, Liu D, Tao D, Xiang W, Xiao X, Wang M, Wang L, Luo G, Li Y, Zeng F, Jiang G. Journal: Mol Cancer Ther. 2016 May;15(5):1029-42. doi: 10.1158/1535-7163.MCT-15-0750. Epub 2016 Mar 3. PubMed |
| 8. | Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression. Author: Shi L, Lin H, Li G, Jin RA, Xu J, Sun Y, Ma WL, Yeh S, Cai X, Chang C. Journal: Mol Cancer Ther. 2016 Apr;15(4):731-42. doi: 10.1158/1535-7163.MCT-15-0706. Epub 2016 Mar 3. PubMed |
| 9. | RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis. Author: Brünker P, Wartha K, Friess T, Grau-Richards S, Waldhauer I, Koller CF, Weiser B, Majety M, Runza V, Niu H, Packman K, Feng N, Daouti S, Hosse RJ, Mössner E, Weber TG, Herting F, Scheuer W, Sade H, Shao C, Liu B, Wang P, Xu G, Vega-Harring S, Klein C, Bosslet K, Umaña P. Journal: Mol Cancer Ther. 2016 May;15(5):946-57. doi: 10.1158/1535-7163.MCT-15-0647. Epub 2016 Apr 1. PubMed |
| 10. | Preclinical Evaluation of AMG 337, a Highly Selective Small Molecule MET Inhibitor, in Hepatocellular Carcinoma. Author: Du Z, Caenepeel S, Shen Y, Rex K, Zhang Y, He Y, Tang ET, Wang O, Zhong W, Zhou H, Huang J, Huang E, Hu L, Coxon A, Zhang M. Journal: Mol Cancer Ther. 2016 Jun;15(6):1227-37. doi: 10.1158/1535-7163.MCT-15-0745. Epub 2016 Mar 29. PubMed |
|
|
  | |
|
以上SCI期刊相关数据和信息来源于网络，仅供参考。
投稿状态统计： 我要评分： | |
同领域作者分享投稿经验：共4条 （包含回复） |
我来分享 |
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2022 中国: LetPub上海分公司 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960
增值电信业务经营许可证：沪B2-20211595
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦2103室
United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451
安全保密
